Skip to main content
Premium Trial:

Request an Annual Quote

Moving on Acquisition Strategy, Magellan Buys Dynex from Capital Genomix

NEW YORK, Oct. 21 (GenomeWeb News) - Magellan Biosciences has acquired Dynex Technologies, a clinical diagnostics and drug-discovery company and the instrumentation division of Capital Genomix, Capital Genomix said today.


Dynex will operate as a subsidiary of Magellan, which was "established to build a leading life science tools company" through "growth and acquisitions," said the statement. Ampersand Ventures owns a majority of Magellan.


"This transaction will provide Capital Genomix with the necessary working capital to accelerate our drug discovery and development programs," James Wishart, Capital Genomics CEO, said in a statement.


Magellan is based in Chelmsford, Mass. Financial details of the transaction were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.